Ocular Therapeutix (NASDAQ:OCUL – Get Free Report)‘s stock had its “outperform” rating restated by equities researchers at Robert W. Baird in a report issued on Thursday, Benzinga reports. They currently have a $18.00 target price on the biopharmaceutical company’s stock. Robert W. Baird’s target price would indicate a potential upside of 390.46% from the stock’s […]
Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report) CEO Antony C. Mattessich bought 6,500 shares of the firm’s stock in a transaction on Wednesday, August 30th. The stock was acquired at an average price of $3.81 per share, for a total transaction of $24,765.00. Following the transaction, the chief executive officer now owns 6,500 shares […]
Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report) was the target of a large decline in short interest during the month of August. As of August 15th, there was short interest totalling 4,920,000 shares, a decline of 20.3% from the July 31st total of 6,170,000 shares. Currently, 6.5% of the shares of the company are […]
Ocular Therapeutix (NASDAQ:OCUL – Get Free Report) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued on Wednesday. Several other research analysts have also weighed in on the company. Robert W. Baird boosted their price target on Ocular Therapeutix from $10.00 to $12.00 in […]
HC Wainwright reiterated their buy rating on shares of Ocular Therapeutix (NASDAQ:OCUL – Free Report) in a research note issued to investors on Tuesday morning, Benzinga reports. HC Wainwright currently has a $12.00 price target on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Ocular Therapeutix’s Q3 2023 earnings at ($0.28) EPS, Q4 […]